KCTD15 and breast carcinoma: Coppola et al. demonstrated that, in patients with HER2 positive breast cancer, KCTD15 was abnormally overexpressed in the cancerous tissues, and its knockdown inhibited the proliferation of SKBR3 cells, and further sensitized these cells to doxorubicin10.